GlassScriptPhysician profile
Amy M Degueme
NPI 1548436371
$142,703.32
in general payments reported to CMS, 2019-2025
26 companies · $54K in 2025
The $54K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $12K · 2021: $20K · 2022: $18K · 2023: $11K · 2024: $8,209 · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Food and Beverage: $6,246 · Travel and Lodging: $3,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,407.31 |
| Food and Beverage | $6,246.46 |
| Travel and Lodging | $3,419.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $137,111.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $869.98 | 2022-2025 | Jardiance, Zepbound, Lyumjev |
| Ibsa Pharma INC. | $545.35 | 2020-2025 | Tirosint, Licart, Tirosint |
| Astrazeneca Pharmaceuticals LP | $499.38 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $498.77 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $497.70 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $489.16 | 2019-2022 | |
| Horizon Therapeutics Plc | $325.62 | 2022-2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $297.48 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $289.81 | 2020-2025 | Tepezza, Evenity, Prolia |
| Ascendis Pharma Endocrinology INC | $218.92 | 2025 | Yorvipath |
| Halozyme INC | $211.98 | 2023 | |
| Medtronic Minimed, INC. | $117.86 | 2019 | |
| Antares Pharma, INC. | $106.58 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Insulet Corporation | $97.21 | 2019-2025 | Omnipod |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $93.38 | 2024-2025 | Korlym |
| Abbott Laboratories | $86.07 | 2020-2022 | |
| Medtronic, INC. | $63.71 | 2023-2025 | Minimed 780g |
| Mannkind Corporation | $59.40 | 2020 | |
| Ascensia Diabetes Care US INC. | $46.60 | 2024-2025 | |
| Astellas Pharma US INC | $44.56 | 2023 | Veozah |
| Tandem Diabetes Care, INC. | $40.49 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $35.89 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $26.92 | 2025 | Rezdiffra |
| Supernus Pharmaceuticals, INC. | $14.75 | 2019 | Xyosted, Tlando |
| Dexcom, INC. | $14.11 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Degueme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.